Finance

Lists
COR:NYSE
Cencora Inc
$317.10
+0.31%
(+0.97) 1D
$317.10
0.00% (0.00)
After hours
Closed: Aug 19, 4:00:11 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for COR...
Open
$314.03
High
$322.50
Low
$312.02
Mkt. cap
14.02B
Avg. vol.
1.49M
Volume
0.00
52-wk high
$377.54
52-wk low
$244.82
Beta
0.57
Shares outstanding
190.83M
No. of employees
49K
Open
$314.03
High
$322.50
Low
$312.02
Mkt. cap
14.02B
Avg. vol.
1.49M
Volume
0.00
52-wk high
$377.54
52-wk low
$244.82
Beta
0.57
Shares outstanding
190.83M
No. of employees
49K
News stories
From web sources and news partners
Profile
Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment. The company is headquartered in Conshohocken, Pennsylvania, part of the Philadelphia metropolitan area. Wikipedia
About Cencora Inc
CEORobert P. Mauch Ph.D.
Employees49K
Founded1871
Headquarters-
SectorHealth care provider
Websitecencora.com
Analyst ratings
Based on 12 analysts giving stock ratings to COR in the past 3 months
Strong buy
Buy
9
Hold
3
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for COR in the last 3 months.
Highest
Current $317.10
$430.00 (+35.60%)
Average
$369.18 (+16.42%)
Lowest
$330.00 (+4.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ryan Halsted
RBC Capital
Hold
Initiated
$330.00
+4.1%
08/19/2026
Glen Santangelo
Barclays
Buy
Reiterated
$350.00
+10.4%
08/13/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$350.00
+10.4%
08/13/2026
Allen Lutz
Bank of America Securities
Hold
Maintained
$330.00
+4.1%
08/12/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
$390.00
+23%
08/10/2026
Stephen Baxter
Wells Fargo
Buy
Reiterated
$395.00
+24.6%
08/11/2026
Charles Rhyee
TD Cowen
Buy
Maintained
$400.00
+26.1%
08/09/2026
Erin Wright
Morgan Stanley
Buy
Reiterated
$346.00
+9.1%
08/07/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
$370.00
+16.7%
08/06/2026
Kevin Caliendo
UBS
Buy
Maintained
$430.00
+35.6%
08/06/2026
Daniel Grosslight
Citi
Buy
Maintained
$370.00
+16.7%
08/06/2026
Ryan Daniels
William Blair
Hold
Reiterated
-
-
08/05/2026
Max Smock
William Blair
Hold
Maintained
-
-
05/22/2026
David Toung
Argus Research
Buy
Reiterated
$400.00
+26.1%
03/17/2026
Last report
Aug 5, 2026
Fiscal period
Q3 2026
EPS / Est. (USD)
$4.48 / $4.35
+3.04%beat
Revenue / Est. (USD)
84.75B / 84.15B
+0.72%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
83.73B
85.93B
78.36B
84.75B
Cost of goods sold
80.78B
82.87B
74.78B
81.15B
Cost of revenue
80.78B
82.87B
74.78B
81.15B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.75B
1.80B
1.98B
2.13B
Operating expense
2.00B
2.06B
2.23B
2.40B
Total operating expenses
82.78B
84.93B
77.01B
83.56B
Operating income
944.58M
1.00B
1.34B
1.20B
Other non operating income
-49.91M
10.10M
-173.00K
16.88M
EBT including unusual items
-187.04M
708.64M
2.09B
996.39M
EBT excluding unusual items
795.23M
941.56M
1.20B
1.08B
Income tax expense
146.03M
142.51M
459.04M
219.73M
Effective tax rate
-78.07%
20.11%
21.98%
22.05%
Other operating expenses
-4.00M
362.00K
595.00K
881.00K
Net income
-339.70M
559.65M
1.64B
763.52M
Net profit margin
-0.41%
0.65%
2.09%
0.90%
Earnings per share
3.84
4.08
4.75
4.48
Interest and investment income
31.52M
20.95M
13.88M
13.82M
Interest expense
-109.36M
-93.36M
-154.34M
-154.52M
Net interest expenses
-77.83M
-72.41M
-140.46M
-140.70M
Depreciation and amortization charges
131.49M
134.29M
132.14M
150.96M
EBITDA
1.21B
1.27B
1.60B
1.47B
Gain or loss from assets sale
-
-35.82M
-234.00K
-15.96M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps